share_log

太平洋4月8日发布研报称，给予君实生物（688180.SH）买入评级。评级理由主要包括：1）2023年公司产品销售收入大幅增长，整体运营效率提升，亏损逐；2）2024年特瑞普利单抗国内医保适应症预计扩至10项，海外商业；3）2024年公司核心管线催化剂丰富。（每日经济新闻）

Pacific released a research report on April 8 stating that it gave Junshi Biotech (688180.SH) a purchase rating. The main reasons for the rating include: 1) the company's product sales revenue increased dramatically in 2023, improving overall operating ef

Zhitong Finance ·  Apr 8 17:44
Pacific released a research report on April 8 stating that it gave Junshi Biotech (688180.SH) a purchase rating. The main reasons for the rating include: 1) the company's product sales revenue increased dramatically in 2023, improving overall operating efficiency, and loss; 2) domestic medical insurance indications for treprilizumab are expected to expand to 10 in 2024, overseas business; 3) the company's core pipeline is rich in catalysts in 2024. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment